Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Helius Medical Technologies, Inc. (HSDT)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.3000+0.1200 (+10.17%)
At close: 04:00PM EDT
1.2900 -0.01 (-0.77%)
After hours: 04:10PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.1800
Open1.1600
Bid1.2000 x 3000
Ask1.3000 x 1000
Day's Range1.1600 - 1.3000
52 Week Range1.0600 - 16.8300
Volume26,678
Avg. Volume857,968
Market Cap5.002M
Beta (5Y Monthly)0.86
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Helius Medical Technologies, Inc. Presents Poster at the 2022 Consortium of Multiple Sclerosis Centers (“CMSC”) Annual Meeting

    -- Study finds significant improvement in gait deficit in multiple sclerosis patients using translingual neurostimulation (“PoNS Therapy®”) combined with a therapeutic exercise program -- -- Poster was one of ten rehabilitation research presentations nominated for the Labe C. Scheinberg Award recognizing the platform or poster, in each therapeutic category, that has the greatest impact in advancing the care of people with MS -- NEWTOWN, Pa., June 06, 2022 (GLOBE NEWSWIRE) -- Helius Medical Techn

  • GlobeNewswire

    Helius Medical Technologies, Inc. Announces Launch of Patient Therapy Access Program for PoNS®

    New program seeks to expand access to patients suffering from multiple sclerosis (MS)NEWTOWN, Pa., June 01, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced the launch of its Patient Therapy Access Program (“PTAP”), which will provide qualifying patients access to on-label Portable Neuromodulation Stimulator (“PoNS”) Therapy at a significantly reduced price. PoNS is indicate

  • GlobeNewswire

    Helius Medical Announces Poster to Be Presented at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Conference

    NEWTOWN, Pa., May 31, 2022 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq: HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that an abstract highlighting real-world data, which shows the impact of translingual neurostimulation as a rehabilitation therapy to improve gait in people with multiple sclerosis (MS), has been selected for a poster presentation at the Consortium for Multiple Sclerosis Centers (CMSC) Annual Meeting tak

Advertisement
Advertisement